POTENSI KO-KEMOTERAPI Na PGV-0 DENGAN DOXORUBICIN TERHADAP BERBAGAI SEL KANKER DAN PENELUSURAN TARGET MOLEKULERNYA PADA JALUR MAP KINASE: PENDEKATAN IN VITRO DAN IN SILICO

• Main Authors: , Endah Puspitasari, , Dr. Agung Endro Nugroho, M.Si., Apt.
• Format: Theses and Dissertations NonPeerReviewed
• Published: [Yogyakarta] : Universitas Gadjah Mada 2012
• Subjects: ETD
• Online Access: https://repository.ugm.ac.id/99855/; http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=56219
• Institution: Universitas Gadjah Mada

Signal transduction disregulation, i.e. MAP kinase pathway leads to degenerative disease development, including cancer. Today, people are seeking for co-chemotherapeutic agent to increase chemotherapeutic agent�s effectiveness and decrease its side effect. Curcumin is a potential chemopreventive agent targeting kinase proteins on their ATP binding site. Thus, Faculty of Pharmacy UGM developed curcumin analogue, PGV-0. Due to its insolubility, Na PGV-0 was then synthesized. This research was done to study Na PGV-0 potential as cochemotherapeutic agent targeting proteins involved in MAP kinase pathway, especially EGFR and IKK, and its effector protein, Pgp and COX-2. Co-chemotherapeutic activity was determined by cytotoxicity single and in combination with doxorubicin on MCF-7 ori, MCF-7/DOX, HeLa, and WiDr cells using MTT assay. While the molecular mechanisms were explored in silico using PLANTS software. Na PGV-0 as ligand was prepared using Marvin Sketch, while protein targets were prepared using YASARA. Na PGV-0 exhibited cytotoxic property on MCF-7 ori, MCF-7/DOX, HeLa, and WiDr cells with IC50 values of 52.33 + 6.36